Lilly

As Millions Lose Weight on GLP-1s, They're Starting to Turn to Retailers to Refresh Their Wardrobes

Lilly’s Foundayo Reaches 1,390 Patients in First Week, Trailing Novo’s Oral Wegovy Launch

Baseline Debuts To Challenge GLP-1 Giant Lilly in Alcohol Use Disorder

Wall Street Slides as S&P 500 Dips 0.1% and Brent Falls to $95 Amid U.S.-Iran Cease‑fire Talks

5 FDA Decisions to Watch in the First Quarter of 2026

Keep an Eye on These 15 Biotech Companies in 2026 

Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes

Roche Breast Cancer Prospect Fails First-Line Test, Shares Fall

AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules

Options Traders Pick Up Pharma Stock After Eli Lilly Buyout

Eli Lilly Isn't Replacing Zepbound -- It's Building an Obesity Empire

Semaglutide Cuts Cardiac Risk 20% and Retatrutide Hits All Diabetes Endpoints

Trump's Obesity Drug Plan for Medicare Would Cost Insurers Billions

STAT+: Pharmalittle: We’re Reading About FDA Seeking More Data on a Lilly Obesity Pill, a Pharma 340B Win, and More

Novartis Breaks Ground on San Diego Biomedical R&D Site

Biotech in 2025: A Retrospective 

Small And Mid-Sized Startup Purchases Are Still Well Below The 2021 Peak

Eli Lilly’s Jaypirca Secures Fourth Phase III Win in CLL, Paving Way for Label Expansion

Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact

Thursday Links: A Job in a System

High-Dose Wegovy Debuts at $399 for Self-Paying Patients

Pfizer’s Early Metsera Data Leaves Analysts Wanting More

TerraPower Commits $450M to Build Radioisotope Production Plant

Breast Cancer Treatments Heat Up: Six Therapies Poised to Transform Patient Outcomes

Anti-Amyloid Alzheimer’s Drugs Show Limited Benefit in Cochrane Review

Lilly’s GLP-1s Mounjaro, Zepbound Push Revenue up 46% in Q4

Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B

Tradipitant

FDA Sets Feb. 1 Launch Date for PreCheck Pilot To Strengthen Domestic Supply Chain

Syremis Therapeutics Raises $165M in Series A Financing

The Next Fed Chair Has Crypto Exposure in His Portfolio. Here Are the Details

Eli Lilly’s Retatrutide Targets Novo Nordisk’s GLP‑1 Stronghold with 28.7% Weight Loss Data

FDA Sends Letters to 2,200 Sponsors, Demanding Public Trial Results

Deals Not Waiting for JPM

Vercel COO Discusses How AI Will Bolster Human Interactions in Sales

How Eli Lilly’s Biotech Collaboration Model Is Rewriting Early-Stage Innovation

USP Adds Tamiflu, Trulicity to Vulnerable List as Upstream Analysis Reshapes Supply Concerns

The Next Generation of GLP-1 Drugs: And How They’ll Reshape Food and Beverage Again

Structure Therapeutics Reports More Phase 2 Data for Oral GLP-1

JPM26: Protagonist Has a $400M Decision To Make. It’s a No-Brainer

3 Trends Shaping the GLP-1 Landscape

Lilly Establishes up to $2.7B Repertoire Deal in Second Immune Play of 2026

Roche Raises NC Manufacturing Investment to $2B To Support Obesity Challenge

Sanegene Bio Closes Over $110 Million Series B

WHO Foundation, Novo Nordisk Collaborate on Childhood Obesity Prevention in India

PharmaShots Quarterly Outlook: The Forces Reshaping Biopharma in Q1 2026

Vanguard to Split Five Equity ETFs 5‑for‑1, Cutting MGK Share Price to ~$70

Bitcoin Makes Minor Gains Following Five Months of Losses

FDA’s CRL Transparency Policy Is Boosting Biopharma Accountability

Bipartisan INSULIN Act Targets $35 Monthly Cap for Private‑Insurance Users

Eli Lilly to Acquire Ventyx Biosciences for $1.2B

Gate Bioscience Secures $65M Series B Round Led by Forbion and Eli Lilly

QuantX Biosciences Secures $85M Series B Funding Led by Lilly and Sanofi Ventures

Eli Lilly to Acquire CrossBridge Bio for up to $300M

Eli Lilly Pays $100M for Rights to CSL’s Clazakizumab

Eli Lilly to Acquire Centessa Pharmaceuticals for $6.3B

Sanegene Bio Secures Over $110M in Series B Funding

Excelsior Sciences Secures $95M Series A Funding Led by Deerfield, Khosla and Sofinnova

Eli Lilly to Acquire Ventyx for $1.2B

Eli Lilly Commits $2.75B to Insilico Medicine for AI‑discovered Drug Candidates

Eli Lilly and Nvidia Sign Five‑year, up to $1 Billion AI Laboratory Deal

Eli Lilly to Acquire Orna Therapeutics for $2.4 Billion